论文部分内容阅读
目的：了解柳氮磺胺吡啶、甲氨蝶呤、雷公藤多甙以及三种药物联合治疗强直性脊柱炎的远期疗效。方法：４６ 例活动性 Ａ Ｓ 分别给予柳氮磺胺吡啶 、甲氨蝶呤、雷公藤多甙以及三种药物联合治疗３ 年以上，通过观察晨僵、腰痛、实验室及放射学检查以及医师与患者全面评价的变化来确定疗效。结果：总临床疗效分别为显效８ ２６ ％ ，有效１５２ ％ 。有５６５ ％ 患者经单种慢作用药治疗可以控制病情发展，６５ ％ 病例需应用两种以上慢作用药，尤其是“重症 Ａ Ｓ”。３７ ％ 患者疗程中因疗效、副作用、药源、经济等问题需要更换其他药物。结论： 柳氮磺胺吡啶、甲氨蝶呤及雷公藤多甙对 Ａ Ｓ 均有不同程度的远期疗效，不失为治疗 Ａ Ｓ 的有效慢作用药。 Ａ Ｓ 治疗应注意个体化。
Objective: To understand the long-term effects of sulfasalazine, methotrexate, tripterygium glycosides and three drugs in the treatment of ankylosing spondylitis. Methods: Forty-six cases of active A S were treated with sulfasalazine, methotrexate, tripterygium wilfordii, and three drugs for more than 3 years respectively. By observing morning stiffness, low back pain, laboratory and radiological examination, The patient’s overall evaluation of the changes to determine the efficacy. Results: The total effective rate was 82.6% and 15.2% respectively. 56.5% of patients treated by a single slow-acting drug can control the progression of the disease, and 6.5% of the patients need to have more than two slow-acting drugs, especially Severe A S. 37% of patients due to treatment efficacy, side effects, drug sources, economic and other issues need to be replaced by other drugs. CONCLUSIONS: Sulfasalazine, methotrexate and tripterygium glycosides have different long-term effects on A s, which are effective slow-acting drugs for the treatment of A s. A S treatment should pay attention to individual.